Skin cancer profiling by multiplex detection
Driven by FDA, NCCN, and ASCO guidelines, our MELANOMASEQ testing results associate Standard of Care specific to skin cancers with a focus on prioritization and support of treatment planning for the physician.
- Comprehensive and integrated services mobilizing complete workups by IHC or Next Generation Sequencing
- Available individual markers, reflexive offerings, and flexible testing designed to meet the cost efficiencies and clinical needs for the patient and physician
- In-network with most managed care providers